Login / Signup

Efficacy and safety of 177 Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.

Dominique S V M ClementShaunak NavalkissoorRajaventhan SrirajaskanthanFrédéric CourbonLawrence O DierickxAmy EcclesValerie LewingtonMercedes MitjavilaJuan Carlos PercovichBenoît LequoyBeilei HeIlya FolitarJohn K Ramage
Published in: European journal of nuclear medicine and molecular imaging (2022)
Lu-DOTATATE for the treatment of patients with advanced, somatostatin receptor-positive panNETs.
Keyphrases
  • neuroendocrine tumors
  • pet ct
  • electronic health record
  • combination therapy
  • replacement therapy